Stock Analysis
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis
Dianthus Therapeutics, Inc. (DNTH) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Dianthus Therapeutics, Inc. (DNTH) currently has an AIQ Score of 56/100, indicating a neutral setup. Risk is the strongest factor at 58/100. Quality is the weakest current factor at 52/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
DNTH at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $91.81 |
| AIQ Score | 56/100 |
| Overall View | Neutral |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $5.26B |
| P/E Ratio (TTM) | 3,060.33 |
| Forward P/E | — |
| EPS (Q3 FY2026) | -$0.81 |
| Revenue (Q3 FY2026) | $1.21M |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.97 |
| Volume | 681.52K |
| 52-week range | $34.29-$117.88 |
| RSI 14 | 62.93 |
| 50-Day SMA | $88.45 |
| 200-Day SMA | $86.93 |
| Analyst Price Target | $134.00 |
| Next Earnings | Mar 8, 2027 |
DNTHDianthus Therapeutics, Inc.
Healthcare / Biotechnology
Relative Leader / Watch
Strong Relative Position
Latest quote
- Momentum58
- Value—
- Quality52
- Risk resilience58
- Sentiment—
DNTH Stock Analysis Summary
Dianthus Therapeutics, Inc. (DNTH) currently has an AIQ Score of 56/100, indicating a neutral setup. Risk resilience is the strongest factor at 58/100. Quality is the weakest current factor at 52/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a neutral regime, DNTH has AIQ Score of 56/100 with Risk resilience base of 58/100 and fading Quality at 52/100. Wait for component alignment before adding exposure.
Healthcare · -0.72% stock move · DNTH classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is DNTH Bullish or Bearish Right Now?
DNTH currently has a neutral overall setup. Momentum is the strongest factor at 58/100, while Quality is weakest at 52/100. The current evidence suggests a mixed rather than strongly bullish or bearish setup.
- - Price is +3.80% above its 50-day SMA.
- - Analyst target implies +45.95% upside from the latest quote.
- - Technical consensus has more buy votes than sell votes (34 vs 10).
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
DNTH's Technical Analysis Consensus is currently Strong Buy, with 34 buy, 2 neutral, and 10 sell votes. DNTH's 14-day RSI is 62.93, which places the stock in a constructive momentum range. DNTH's beta is 0.97, indicating market sensitivity broadly in line with the market.
What Changed in DNTH?
The largest recent change in DNTH is Momentum moving up by 5.0 points over the available 7-day comparison window. Momentum remains the strongest visible factor.
What Would Change the DNTH Outlook?
The current neutral outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
DNTH Decision Framework
Public evidence layers, setup checks, and risk context for Dianthus Therapeutics, Inc..
Dianthus Therapeutics, Inc. (DNTH) Stock Analysis
Dianthus Therapeutics, Inc. has an AIQ Score of 56/100 in a Neutral regime. Momentum is strongest at 58/100. Beta is 0.97, close to market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | DNTH is in a Neutral AIQ regime with score 56/100. |
| Signal Conflict | The primary conflict is that momentum leads at 58/100 while quality lags at 52/100. |
| Factor Evidence | Momentum 58/100 · Quality 52/100 · Risk 58/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Momentum is the strongest factor at 58/100.
Momentum is 58/100 and RSI (14) is 62.9.
DNTH is in a Neutral regime at 56/100.
Risk factor is 58/100 with beta 0.97 and annual volatility 59.79%.
Current conflict: momentum leads at 58/100 while quality lags at 52/100.
DNTH Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
DNTH Fundamentals
DNTH valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
DNTH Technical Analysis
DNTH technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
DNTH Stock Catalysts
Track DNTH earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
DNTH Dividend Analysis
DNTH dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
DNTH Financial Data
DNTH revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
DNTH Risk Analysis
DNTH volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
DNTH Stock News
DNTH stock news, market tone, recent headlines, and catalyst context.
DNTH vs Biotechnology Peers
Current peer cohort: DNTH · DYN · ELVN · ERAS · EWTX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| DNTH Current stock | 56/100 | — | 58/100 | 58/100 | 1.82 | 59.79% | Current |
| DYN Dyne Therapeutics, Inc. | 48/100 | — | 52/100 | 42/100 | 0.11 | 63.89% | DNTH vs DYN |
| ELVN Enliven Therapeutics, Inc. | 71/100 | — | 66/100 | 56/100 | 1.43 | 78.19% | DNTH vs ELVN |
| ERAS Erasca, Inc. | 61/100 | — | 67/100 | 39/100 | 2.29 | 102.70% | DNTH vs ERAS |
| EWTX Edgewise Therapeutics, Inc. | 72/100 | — | 82/100 | 57/100 | 1.41 | 73.21% | DNTH vs EWTX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for DNTH: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching DNTH
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for DNTH
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
DNTH Stock FAQ
What is DNTH stock price today?
Dianthus Therapeutics, Inc.'s current stock price is $91.81. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is DNTH bullish or bearish right now?
DNTH's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is DNTH's market cap?
DNTH's market cap is $5.26B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is DNTH's current P/E ratio?
DNTH's current P/E ratio is 3,060.33 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is DNTH's RSI?
DNTH's 14-day RSI is 62.93 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is DNTH above its 50-day and 200-day moving averages?
DNTH is 3.80% from its 50-day SMA and 5.62% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is DNTH's next earnings date?
DNTH's next earnings date is currently listed as Mar 8, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does DNTH pay a dividend?
DNTH's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.